---
figid: PMC5784573__10.1177_1758834017742575-fig2
figlink: /pmc/articles/PMC5784573/figure/fig2-1758834017742575/
number: F2
caption: Mechanistic changes in the antitumor immune response after radiotherapy.(I)
  RT triggers the recruitment of DCs to the tumor site by inducing adenosine triphosphate
  release.– Subsequently, calreticulin is translocated to the tumor cell surface,
  which triggers their phagocytosis., HMGB1 released after RT promotes processing
  and cross-presentation of tumor antigens taken up by DCs., Moreover, phagocytosis
  of irradiated tumor cells activates the cytosolic DNA sensing cGAS/STING pathway
  leading to the induction of IFN-β. This, together with complement activated by RT
  leads to DC maturation.– (II) DCs then migrate to the tumor-draining lymph nodes
  and prime CD8+ T cells,, which express high levels of PD-1, thus representing optimal
  targets for checkpoint inhibitors.,, In combination with IT, low-dose irradiation
  facilitates T-cell extravasation, which is mediated by iNOS+ macrophages and further
  perpetuated by the IFN-γ-dependent induction of adhesion molecules on the endothelium.,
  After RT alone, immunosuppressive CD11b+ cells are recruited from the bone marrow
  and drive tumor regrowth and vasculogenesis and in an MMP-9-dependent manner.– These
  CD11b+ myeloid cells are lured into the tumor tissue by radiation-induced CSF-1,
  CCL2 or CXCL12.,,– Of note, the TME after RT fosters the secretion of CXCL12 by
  TGF-β and NO-mediated upregulation of HIF-1α., In contrast to these immunosuppressive
  chemokines, CXCL16 and CXCL9/10 can attract cytotoxic T cells and thereby enhance
  IT efficacy.– (III) Once T cells activated by RT have infiltrated the tumor tissue,
  they encounter a heavily modified TME, which, in conjunction with IT, they can also
  modulate by killing immunosuppressive MDSCs by TNF-α or in a TCR-dependent manner.–
  Radiation induces a plethora of cytokines including type I and II IFNs, which, next
  to their already-discussed functions, can directly activate leukocytes and have
  direct cytotoxic effects on tumor cells.,, However, several immunosuppressive cytokines
  are released into the TME post-RT such as TGF-β and IL-6 leading to epithelial–mesenchymal
  transition, invasiveness and radioresistance.,, IT helps to shift the post-RT cytokine
  milieu towards antitumor immunity. RT also alters IT efficacy by quantitative and
  qualitative changes in tumor-infiltrating immunosuppressive leukocytes. CD11b+ myeloid
  cells expand due to CSF-1 induction and depending on radiation-dose macrophages,
  are skewed towards an M1- or M2-like phenotype, with the latter being sequestered
  in hypoxic areas.,,– In addition, Tregs accumulate due to priming by Langerhans
  cells and their intrinsic radioresistance., (IV) Finally, RT induces the expression
  of several molecules and receptors on the tumor cell surface, like MHC-I molecules,,
  TNFR superfamily members,– ATM-dependent induction of ligands for the NKG2D receptor–
  and calreticulin, leading to enhanced tumor cell killing by CD8+ T and NK cells.,,,
  However, RT can also induce excess levels of PD-L1 on tumor cells and thereby induce
  T-cell anergy underlining the rationale for combining RT and IT.,,,–ATM, ataxia
  teleangiectasia mutated; ATP, adenosine triphosphate; cGAS, cyclic GMP-AMP synthase;
  CCL, C-C motif chemokine ligand; CSF-1, colony stimulating factor-1; CXCL, C-X-C
  motif chemokine ligand; DC, dendritic cell; HIF-1α, hypoxia-inducible factor-1 alpha;
  HMGB1, high mobility group box 1; IFN, interferon; IL, interleukin; iNOS, nitric
  oxide synthase 2; IT, immunotherapy; LGP2, laboratories of genetics and physiology
  2; M1, M1-like macrophage (iNOShi, Arg1lo, Fizz-1lo); M2, M2-like macrophage (iNOSlo
  Arg1hi, Fizz-1lo) MDSC, myeloid-derived suppressor cell; MHC-I, major histocompatibility
  complex I; MMP-9, matrix metalloproteinase 9; NK, natural killer cell; NKG2D, killer
  cell lectin-like receptor K1; NO, nitric oxide; PD-1, programmed-cell-death 1; PD-L1,
  programmed-cell-death ligand 1, CD274 molecule; RT, radiotherapy; STING, transmembrane
  protein 173; TCR, T cell receptor; TGF-β, transforming growth-factor beta, TME,
  tumor microenvironment; TNF, tumor necrosis factor; TNFR, tumor necrosis factor
  receptor; Treg, regulatory T cell.
pmcid: PMC5784573
papertitle: 'Radiation effects on antitumor immune responses: current perspectives
  and challenges.'
reftext: Thomas Walle, et al. Ther Adv Med Oncol. 2018;10:1758834017742575.
pmc_ranked_result_index: '234809'
pathway_score: 0.9467708
filename: 10.1177_1758834017742575-fig2.jpg
figtitle: 'Radiation effects on antitumor immune responses: current perspectives and
  challenges.'
year: '2018'
organisms:
- Homo sapiens
ndex: 83a5d758-defc-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5784573__10.1177_1758834017742575-fig2.html
  '@type': Dataset
  description: Mechanistic changes in the antitumor immune response after radiotherapy.(I)
    RT triggers the recruitment of DCs to the tumor site by inducing adenosine triphosphate
    release.– Subsequently, calreticulin is translocated to the tumor cell surface,
    which triggers their phagocytosis., HMGB1 released after RT promotes processing
    and cross-presentation of tumor antigens taken up by DCs., Moreover, phagocytosis
    of irradiated tumor cells activates the cytosolic DNA sensing cGAS/STING pathway
    leading to the induction of IFN-β. This, together with complement activated by
    RT leads to DC maturation.– (II) DCs then migrate to the tumor-draining lymph
    nodes and prime CD8+ T cells,, which express high levels of PD-1, thus representing
    optimal targets for checkpoint inhibitors.,, In combination with IT, low-dose
    irradiation facilitates T-cell extravasation, which is mediated by iNOS+ macrophages
    and further perpetuated by the IFN-γ-dependent induction of adhesion molecules
    on the endothelium., After RT alone, immunosuppressive CD11b+ cells are recruited
    from the bone marrow and drive tumor regrowth and vasculogenesis and in an MMP-9-dependent
    manner.– These CD11b+ myeloid cells are lured into the tumor tissue by radiation-induced
    CSF-1, CCL2 or CXCL12.,,– Of note, the TME after RT fosters the secretion of CXCL12
    by TGF-β and NO-mediated upregulation of HIF-1α., In contrast to these immunosuppressive
    chemokines, CXCL16 and CXCL9/10 can attract cytotoxic T cells and thereby enhance
    IT efficacy.– (III) Once T cells activated by RT have infiltrated the tumor tissue,
    they encounter a heavily modified TME, which, in conjunction with IT, they can
    also modulate by killing immunosuppressive MDSCs by TNF-α or in a TCR-dependent
    manner.– Radiation induces a plethora of cytokines including type I and II IFNs,
    which, next to their already-discussed functions, can directly activate leukocytes
    and have direct cytotoxic effects on tumor cells.,, However, several immunosuppressive
    cytokines are released into the TME post-RT such as TGF-β and IL-6 leading to
    epithelial–mesenchymal transition, invasiveness and radioresistance.,, IT helps
    to shift the post-RT cytokine milieu towards antitumor immunity. RT also alters
    IT efficacy by quantitative and qualitative changes in tumor-infiltrating immunosuppressive
    leukocytes. CD11b+ myeloid cells expand due to CSF-1 induction and depending on
    radiation-dose macrophages, are skewed towards an M1- or M2-like phenotype, with
    the latter being sequestered in hypoxic areas.,,– In addition, Tregs accumulate
    due to priming by Langerhans cells and their intrinsic radioresistance., (IV)
    Finally, RT induces the expression of several molecules and receptors on the tumor
    cell surface, like MHC-I molecules,, TNFR superfamily members,– ATM-dependent
    induction of ligands for the NKG2D receptor– and calreticulin, leading to enhanced
    tumor cell killing by CD8+ T and NK cells.,,, However, RT can also induce excess
    levels of PD-L1 on tumor cells and thereby induce T-cell anergy underlining the
    rationale for combining RT and IT.,,,–ATM, ataxia teleangiectasia mutated; ATP,
    adenosine triphosphate; cGAS, cyclic GMP-AMP synthase; CCL, C-C motif chemokine
    ligand; CSF-1, colony stimulating factor-1; CXCL, C-X-C motif chemokine ligand;
    DC, dendritic cell; HIF-1α, hypoxia-inducible factor-1 alpha; HMGB1, high mobility
    group box 1; IFN, interferon; IL, interleukin; iNOS, nitric oxide synthase 2;
    IT, immunotherapy; LGP2, laboratories of genetics and physiology 2; M1, M1-like
    macrophage (iNOShi, Arg1lo, Fizz-1lo); M2, M2-like macrophage (iNOSlo Arg1hi,
    Fizz-1lo) MDSC, myeloid-derived suppressor cell; MHC-I, major histocompatibility
    complex I; MMP-9, matrix metalloproteinase 9; NK, natural killer cell; NKG2D,
    killer cell lectin-like receptor K1; NO, nitric oxide; PD-1, programmed-cell-death
    1; PD-L1, programmed-cell-death ligand 1, CD274 molecule; RT, radiotherapy; STING,
    transmembrane protein 173; TCR, T cell receptor; TGF-β, transforming growth-factor
    beta, TME, tumor microenvironment; TNF, tumor necrosis factor; TNFR, tumor necrosis
    factor receptor; Treg, regulatory T cell.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CGAS
  - CD86
  - CXCL9
  - TRG
  - TNF
  - VCAM1
  - CXCL12
  - TLR4
  - CXCL13
  - CXCL1
  - CXCL3
  - CXCL14
  - TRA
  - CXCL8
  - CXCL10
  - IFNA1
  - IFNAR1
  - IFNB1
  - IL6
  - DHX58
  - CSF1
  - CXCL2
  - CXCL16
  - TRB
  - TGFB1
  - TGFB2
  - TGFB3
  - CD8A
  - CD8B
  - CD80
  - CXCL6
  - CXCL11
  - CXCL5
  - PDCD1
  - CD274
  - TMEM173
  - FAS
  - FASLG
  - HMGB1
  - ICAM1
  - ITGAM
  - PF4
  - PPBP
  - TRD
  - CCL2
  - KLRK1
  - C3AR1
  - ATM
  - CD28
  - C5AR1
  - ATP
  - TCR MHCH
  - TCR
  - cytotoxicity
genes:
- word: CGAS
  symbol: CGAS
  source: hgnc_symbol
  hgnc_symbol: CGAS
  entrez: '115004'
- word: CD80/86
  symbol: CD86
  source: hgnc_symbol
  hgnc_symbol: CD86
  entrez: '942'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: VCAM-1
  symbol: VCAM1
  source: hgnc_symbol
  hgnc_symbol: VCAM1
  entrez: '7412'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: TLR4
  symbol: TLR4
  source: hgnc_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: IFN-
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFN-a
  symbol: IFN-ALPHA
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFNAR
  symbol: IFNAR
  source: hgnc_prev_symbol
  hgnc_symbol: IFNAR1
  entrez: '3454'
- word: IFN-B
  symbol: IFNB
  source: bioentities_symbol
  hgnc_symbol: IFNB1
  entrez: '3456'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: LGP2
  symbol: LGP2
  source: hgnc_alias_symbol
  hgnc_symbol: DHX58
  entrez: '79132'
- word: CSF-1
  symbol: CSF1
  source: hgnc_symbol
  hgnc_symbol: CSF1
  entrez: '1435'
- word: CXCL10
  symbol: CXCL10
  source: hgnc_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCL16
  symbol: CXCL16
  source: hgnc_symbol
  hgnc_symbol: CXCL16
  entrez: '58191'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: CD80/86
  symbol: CD80
  source: hgnc_symbol
  hgnc_symbol: CD80
  entrez: '941'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: STING
  symbol: STING
  source: hgnc_alias_symbol
  hgnc_symbol: TMEM173
  entrez: '340061'
- word: Fas
  symbol: FAS
  source: hgnc_symbol
  hgnc_symbol: FAS
  entrez: '355'
- word: FasL
  symbol: FasL
  source: hgnc_alias_symbol
  hgnc_symbol: FASLG
  entrez: '356'
- word: HMGB1
  symbol: HMGB1
  source: hgnc_symbol
  hgnc_symbol: HMGB1
  entrez: '3146'
- word: ICAM-1
  symbol: ICAM1
  source: hgnc_symbol
  hgnc_symbol: ICAM1
  entrez: '3383'
- word: CD11b+
  symbol: CD11b
  source: hgnc_alias_symbol
  hgnc_symbol: ITGAM
  entrez: '3684'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: CCL2
  symbol: CCL2
  source: hgnc_symbol
  hgnc_symbol: CCL2
  entrez: '6347'
- word: NKG2D
  symbol: NKG2-D
  source: hgnc_alias_symbol
  hgnc_symbol: KLRK1
  entrez: '22914'
- word: C3aR1
  symbol: C3AR1
  source: hgnc_symbol
  hgnc_symbol: C3AR1
  entrez: '719'
- word: ATM
  symbol: ATM
  source: hgnc_symbol
  hgnc_symbol: ATM
  entrez: '472'
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: C5aR1
  symbol: C5AR1
  source: hgnc_symbol
  hgnc_symbol: C5AR1
  entrez: '728'
chemicals:
- word: ATP
  source: MESH
  identifier: D000255
- word: TCR MHCH
  source: MESH
  identifier: D017260
- word: TCR
  source: MESH
  identifier: D017260
diseases:
- word: cytotoxicity
  source: MESH
  identifier: D064420
figid_alias: PMC5784573__F2
redirect_from: /figures/PMC5784573__F2
figtype: Figure
---
